A new inhibitor in treating small cell lung cancer

A team of researcher from Manchester University reveals that a new drug could prove useful in treating small cell lung cancer — the most aggressive form of lung cancer. The article was published in Clinical Cancer Research.

In the study, researchers tested AZD3965 that targets one of these molecules, MCT1, in lung cancer cells and in mouse models. In cancer cells there is a switch to using glycolysis, a process that requires less oxygen and produces lactate as a by-product. Certain molecules — monocarboxylate transporters (MCTs) — are involved in the movement of lactate out of cells and drugs that target MCTs have been shown to stop tumour growth. The study showed that in those cells lacking an alternate lactate transporter, MCT4, the drug had an effect. They found that AZD3965 increased the level of lactate in cells and, more importantly, reduced tumour growth. Through tumour samples taken from lung cancer patients, found that high levels of MCT1 were linked to worse patient prognosis.

AZD3965 is currently in clinical trials, but it has not yet been tested in small cell lung cancer.”Even that, The results are promising and certainly provide encouragement to test this treatment clinically in patients with small cell lung cancer. With the deep research. We hope that AZD3965 maybe be a potential novel cancer treatment

This article is extract from


Comments are closed.